Armata Secures $2.5M DoD Funding for AP-SA02
LOS ANGELES, Calif. | June 23, 2026 Armata Pharmaceuticals has received an additional $2.5 million in non-dilutive funding from...
MRSA
Advertisement
Acurx Pharmaceuticals Showcases DNA pol IIIC Antibiotic Breakthrough
STATEN ISLAND, N.Y., June 16, 2026 Acurx Pharmaceuticals has announced the presentation of new scientific findings from its ongoing...
Armata Gains FDA Fast Track for AP-SA02 Therapy
LOS ANGELES, May 7, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Armata Announces Phase 2a Success for S. aureus Phage Therapy
Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...
Advertisement
